Life Science REIT PLC Director Declaration (8110P)
11 Octubre 2023 - 5:32AM
UK Regulatory
TIDMLABS
RNS Number : 8110P
Life Science REIT PLC
11 October 2023
11 October 2023
LEI 213800RG7JNX7K8F7525
Life Science REIT plc
("Life Science REIT" or the "Company")
Director Declaration
Claire Boyle, Chair and Non-Executive Director of Life Science
REIT, has been appointed to the Board of Nippon Active Value Fund
plc, a company listed on the London Stock Exchange, with effect
from 10 October 2023. In addition, Claire Boyle has resigned from
her appointment as an Independent Non-Executive Director of abrdn
Japan Investment Trust plc with effect from 10 October 2023.
This disclosure is made in accordance with Listing Rule
9.6.14.
Enquiries:
Link Company Matters Limited - Company
Secretary
labs_cosec@linkgroup.co.uk
Ironstone Asset Management - Investment
Adviser
Simon Farnsworth/ Joanna Waddingham via Buchanan below
Panmure Gordon - Joint Corporate Broker +44 20 7886 2500
Alex Collins / Tom Scrivens
Jefferies International Limited - Joint
Corporate Broker +44 20 7029 8000
Tom Yeadon / Andrew Morris / Oliver Nott
G10 Capital Limited - AIFM +44 20 7397 5450
Verity Morgan-Jones / Paul Cowland
Buchanan - Financial PR +44 20 7466 5000
Mark Court / Henry Wilson / Verity Parker
LifeSciencereit@buchanan.uk.com
Notes to editors
Life Science REIT plc is a specialist property business focused
on the UK's growing life science sector. The Company's portfolio of
assets is located across the "Golden Triangle" of research and
development hubs in Oxford, Cambridge and London's Knowledge
Quarter and its strategic vision is to become the property provider
of choice for life science companies in the UK.
Life Science REIT is addressing the acute demand-supply
imbalance for laboratory space in the "Golden Triangle", which is
characterised by low vacancy rates and prime rental increases. The
UK life science sector itself is benefiting from a buoyant
early-stage funding environment, driving demand for laboratory
space.
The Company's diverse portfolio of assets ranges from a 20-acre
science park currently under development through to fully let
buildings, with an important part of the Company's strategy being
the conversion of existing properties to laboratory space.
The Company's investment policy is focused on capital growth
whilst also providing a growing level of income.
Life Science REIT trades on the Main Market of the London Stock
Exchange under the ticker LABS.
Further information is available at
https://lifesciencereit.co.uk . To sign up for email alerts, please
visit https://lifesciencereit.co.uk/investors/ .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RDNZZMMGGMLGFZM
(END) Dow Jones Newswires
October 11, 2023 06:32 ET (10:32 GMT)
Life Science Reit (LSE:LABS)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Life Science Reit (LSE:LABS)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024